Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27561548 | 1.00 | AKR1B1 (0.33) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL98729 | 1.00 | AKR1B1 (0.33) | AKR1B1LMNAL3MBTL1TDP1 | |
| Water SCHEMBL28186002 | 0.98 | AKR1B1 (0.32) | AKR1B1LMNAL3MBTL1 | |
| SCHEMBL28599341 | 0.89 | — | — | |
| SCHEMBL25264497 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL671071 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL28985161 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL6795503 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL599601 | 0.87 | LMNA (0.40) | AKR1B1LMNAL3MBTL1TDP1 | |
| SCHEMBL16513133 | 0.80 | AKR1B1 (0.32) | AKR1B1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6676 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393511-A1 | LIPID COMPOUND AND USE THEREOF | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | claimed |
| EP-4393484-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | claimed |
| US-11976279-B2 | Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors | EMORY UNIVERSITY (US) | 2024-05-07 | — | — | US | claimed |
| US-11851656-B2 | Chemically modified single-stranded RNA-editing oligonucleotides | PROQR THERAPEUTICS II B.V. (NL) | 2023-12-26 | — | — | US | claimed |
| CN-116744942-A | MICRORNA-29 compounds, compositions and therapeutic uses thereof | 高士威治疗有限公司 | 2023-09-12 | — | — | CN | claimed |
| EP-4232580-A2 | MICRORNA-29 COMPOUNDS, COMPOSITIONS AND USES IN THERAPY | Causeway Therapeutics Limited (GB) | 2023-08-30 | — | — | EP | claimed |
| CN-116410978-A | Small interfering nucleic acid, preparation and application thereof | 佑嘉(杭州)生物医药科技有限公司 | 2023-07-11 | — | — | CN | claimed |
| CN-110352244-B | Chemically modified RNA editing single stranded oligonucleotides | ProQR治疗上市公司Ⅱ | 2023-03-21 | — | — | CN | claimed |
| US-20230039928-A1 | Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease | PROQR THERAPEUTICS II B.V. (NL) | 2023-02-09 | — | — | US | claimed |
| CN-113186203-B | Vaccine agent for treating or preventing coronavirus diseases | 斯微(上海)生物科技股份有限公司 | 2022-12-30 | — | — | CN | claimed |
| US-20070072796-A1 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | ASTEX PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | claimed |
| US-20060292603-A1 | Method for selecting a chemical entity from a tagged library | NUEVOLUTION A/S (DK) | 2006-12-28 | — | — | US | claimed |
| US-20060286581-A1 | Heteroconfigurational Polynucleotides and Methods of Use | APPLERA CORPORATION; APPLIED BIOSYSTEMS GROUP (US) | 2006-12-21 | — | — | US | claimed |
| EP-1465913-A1 | HETEROCONFIGURATIONAL POLYNUCLEOTIDE AND METHODS OF USE | Applera Corporation (US) | 2004-10-13 | — | — | EP | claimed |
| US-20030198980-A1 | Comprising a D-form polynucleotide sequence portion and an L-form polynucleotide sequence portion that are covalently linked | APPLERA CORPORATION | 2003-10-23 | — | — | US | claimed |
| WO-2003059929-A1 | HETEROCONFIGURATIONAL POLYNUCLEOTIDE AND METHODS OF USE | APPLERA CORPORATION (US) | 2003-07-24 | — | — | WO | claimed |
| CN-1113892-C | Process for preparation of 2'-fluoro-5-methyl-beta-L-arabino-furanosyluridine | UNIV OF GEORGIA RES FOUNDATION (US) | 2003-07-09 | — | — | CN | claimed |
| US-6548298-B2 | Transcriptional unit complementary to human telomerase RNA sequence linked to regulating sequences | GERON CORPORATION | 2003-04-15 | — | — | US | claimed |
| US-6512107-B2 | Generating preferential uridine derivative | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION | 2003-01-28 | — | — | US | claimed |
| US-5958680-A | NUCLEIC ACIDS COMPRISING THE RNA COMPONENT OF A MAMMALIAN TELOMERASE ARE USEFUL AS PHARMACEUTICAL, THERAPEUTIC, AND DIAGNOSTIC REAGENTS. | GERON CORPORATION (US) | 1999-09-28 | — | — | US | claimed |